Enfortumab Vedotin
Enfortumab Vedotin is a pharmaceutical drug with 56 clinical trials. Currently 43 active trials ongoing. Historical success rate of 70.0%.
Success Metrics
Based on 7 completed trials
Phase Distribution
Phase Distribution
15
Early Stage
32
Mid Stage
7
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
70.0%
7 of 10 finished
30.0%
3 ended early
43
trials recruiting
56
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer ( EV-309 )
Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
Clinical Trials (56)
Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer ( EV-309 )
Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma
Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Enfortumab Vedotin in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-based Combination Therapy
A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 56